参考文献/References:
[1] 玉超勇.Graves病研究新进展.医学综述,2008,14(18):2805-2807.
[2] 刘艳,付立武,魏月芳,等.131I与抗甲状腺药物治疗Graves甲亢的疗效评价.河南科技大学学报(医学版),2008,26(4):265-266.
[3] 祝学光.外科学,颈部疾病.5版.北京:人民卫生出版社,2002:337-338.
[4] 陈再君.131碘治疗甲状腺疾病的研究现状.临床荟萃,2004,19(4):228-229.
[5] 陈华,宋丁.131I治疗Graves病甲状腺机能亢进症的5年随访研究.华西医学,2008,23(2):272-273.
[6] Kraft O,Stepien A.Functional autonomies of thyroid and efficacy of radioiod-ine therapy.Cancer Biother Radiopharm,2007,22(2):261-267.
[7] 肖海鹏,王深明.甲状腺功能亢进症的临床诊疗思维.新医学,2005,36(1):53-55.
[8] 李林,沈绍群.131I固定剂量法治疗甲亢近期疗效观察.四川大学学报(医学版),2005,36(5):752-753.
[9] 熊星辉,覃伟武.131I治疗甲亢的进展与现状.中国临床新医学,2009,2(3):301-303.
[10] Allahabadia A,Daykin J,Sheppard MC,et al.Radioiodinetreatment of hyperthyroidismprognostic factors for outcome J Clin Endocrinol Metab,2001,86(8):3611-3617.
[11] 戴红,陈炎斌,张笑丹,唐亦复.不同方法治疗Graves病的回顾性对比研究.武警医学,2008,19(8):693-696.
[12] Jin JH,Zhang XJ,Yu HM,et al.Outcome of radioiodine-131 therapy in Graves disease:A retrospective analysis for 3603 cases.J Nucl Med,2008,49(Suppl 1):89P.
[13] Leslie WD,Ward L,Salamon EA,et al.A randomized comparison of radioiodine doses in Graves’ hyperthyroidism.J Clin Endocrinol Metab,2003,88(3):978-983.
[14] 龙少康,王小玲,梁新蓉,等.131I治疗甲亢及引起甲减危险因素的国内外研究概况.现代预防医学,2009,36(5):991-992.
[15] Shi GM,Xu Q,Zhu CY,et al.Influence of propylthiouracil and methimazole pre-treatment on the outcome of iodine-131 therapy inhyperthyroid patients with Graves’ disease.J Int Med Res,2009,37(2):576-582.
[16] El Refaei SM,Shawkat W.Long-term carbimazole intake does not affect success rate of radioactive 131 Iodine in treatment of Graves’ hyperthyroidism.Nucl Med Commun,2008,29(7):642-648.
[17] Walter MA,Müller-Brand J,Müller B.Antithyroid drugs and radioiodine and the absence of evidence.J Nucl Med,2007,48(8):1403-1404.
[18] Walter MA,Briel M,Christ-Crain M,et al.Effects of antithyroid drugs on radioiodine treatment:systematic review and meta-analysis of randomised controlled trials.BMJ,2007,334(7594):514.
[19] 郑薇,谭建,贾春霞,等.抗甲状腺药物对131I治疗Graves病疗效影响.中外医疗,2008,27(7):3-5.
[20] 孙云钢,蒋宁一.131I治疗Graves’病的临床应用进展.中国医疗前沿,2009(5):26-28.
[21] Rivkees S.Radioactive iodine use in childhood Graves’ disease:time to wake up and smell the 1-131.J Clin Endocrinol Metab,2004,89(9):4227-4228.
[22] Franklyn JA,Sheppard MC,Maisonneuve P.Thyroid function and mortality in patients treated for hyperthyroidism.JAMA,2005,294(1):71-80.
[23] Franklyn JA,Maisonneuve P,Sheppard M,et al.Cancer incidence and mortality after radioiodine treatment for hyperthyroidism:a population -based cohort study.Lancet,1999,353(9170):2111-2115.
[24] Ceccarelli C,Canale D,Vitti P.Radioactive iodine (131I) effects on male fertility.Curr Opin Urol,2008,18(6):598-601.
相似文献/References:
[1]邓艳,张伟.125I-碘酞酸盐临床应用进展[J].国际放射医学核医学杂志,2016,40(3):225.[doi:10.3760/cma.j.issn.1673-4114.2016.03.012]
Deng Yan,Zhang Wei.125I-iothalamate clinical applications[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):225.[doi:10.3760/cma.j.issn.1673-4114.2016.03.012]
[2]杨珂,唐波,于夕荣,等.甲状腺癌131i治疗病房的辐射屏蔽计算与评价[J].国际放射医学核医学杂志,2015,39(5):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
yang ke,tang bo,yu xirong,et al.shielding calculation and assessment in 131i therapy for thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
[3]刘娇,程兵,常伟,等.非高危分化型甲状腺癌低剂量和高剂量131I清甲疗效的分析[J].国际放射医学核医学杂志,2016,40(6):419.[doi:10.3760/cma.j.issn.1673-4114.2016.06.004]
Liu Jiao,Cheng Bing,Chang Wei,et al.Ablation efficacy in non-high-risk differentiated thyroid carcinoma patients with low-dose and high-dose 131I[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):419.[doi:10.3760/cma.j.issn.1673-4114.2016.06.004]
[4]徐蓉生,梅艳,赵力威,等.B超引导下术中125I粒子植入治疗晚期胰腺癌的疗效评价[J].国际放射医学核医学杂志,2016,40(6):424.[doi:10.3760/cma.j.issn.1673-4114.2016.06.005]
Xu Rongsheng,Mei Yan,Zhao Liwei,et al.Evaluation of 125I particle implantation in the treatment of patients with advanced pancreatic neoplasms using B ultrasound-guided surgery[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):424.[doi:10.3760/cma.j.issn.1673-4114.2016.06.005]
[5]张丽花,蒋宁一.131I治疗Graves甲亢合并肝功能损害或血细胞减少的优势与风险[J].国际放射医学核医学杂志,2015,39(6):483.[doi:10.3760/cma.j.issn.1673-4114.2015.06.010]
Zhang Lihua,Jiang Ningyi.The advantage and risk of 131I treatment in hyperthyroidism combined with liver injury or blood cell reduction[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):483.[doi:10.3760/cma.j.issn.1673-4114.2015.06.010]
[6]杨宝军.131I治疗甲亢合并特发性血小板减少性紫癜一例[J].国际放射医学核医学杂志,2015,39(6):511.[doi:10.3760/cma.j.issn.1673-4114.2015.06.017]
[7]赵腾,梁军,林岩松.131I治疗前刺激性Tg在分化型甲状腺癌风险评估及治疗决策中的意义[J].国际放射医学核医学杂志,2015,39(1):61.[doi:10.3760/cma.j.issn.1673-4114.2015.01.013]
Zhao Teng,Liang Jun,Lin Yansong.The role of preablative stimulated thyroglobulin in guiding risk estimation and therapeutic decisions of differentiated thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):61.[doi:10.3760/cma.j.issn.1673-4114.2015.01.013]
[8]胡小春,蒋宁一,李敬彦,等.硒对经131I治疗Graves病患者血清甲状腺过氧化物酶抗体水平的影响[J].国际放射医学核医学杂志,2015,39(2):140.[doi:10.3760/cma.j.issn.1673-4114.2015.02.008]
Hu Xiaochun,Jiang Ningyi,Li Jingyan,et al.Effect of additional selenium on the levels of serum thyroid peroxidase antibody in patients with Graves disease treated with 131I[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):140.[doi:10.3760/cma.j.issn.1673-4114.2015.02.008]
[9]杨翠红,刘金剑,褚丽萍,等.125I标记注射用干扰素α2b(假单胞菌)研究雾化吸入与肌肉注射的代谢及组织分布差异[J].国际放射医学核医学杂志,2015,39(3):191.[doi:10.3760/cma.j.issn.1673-4114.2015.03.001]
Yang Cuihong,Liu Jinjian,Chu Liping,et al.Pharmacokinetics and tissue distribution of interferon α2b（Pseudomonas putida）administered via atomization inhalation and intramuscular injection by 125I labeling[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):191.[doi:10.3760/cma.j.issn.1673-4114.2015.03.001]
[10]陈雪梅,周树云,范源,等.表没食子儿茶素没食子酸酯对131I辐射损伤所致甲减大鼠模型抗氧化体系的保护作用[J].国际放射医学核医学杂志,2015,39(4):311.[doi:10.3760/cma.j.issn.1673-4114.2015.04.009]
Chen Xuemei,Zhou Shuyun,Fan Yuan,et al.Protection of antioxidant system of EGCG on the thyroid in rat model from 131I radiation damage[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):311.[doi:10.3760/cma.j.issn.1673-4114.2015.04.009]
[11]梁雯丽,郑艳,李娜,等.Graves甲亢患者131I治疗后早期TRAb及TSAb变化的研究分析[J].国际放射医学核医学杂志,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
Liang Wenli,Zheng Yan,Li Na,et al.Analysis of the changes in early TRAb and TSAb after 131I treatment for patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
[12]田琦,蒋宁一,郑丽.265例精细个体化131I治疗Graves甲亢的疗效观察[J].国际放射医学核医学杂志,2016,40(4):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
Tian Qi,Jiang Ningyi,Zheng Li.Therapeutic effect of fine individual 131I treatment on Graves disease hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
[13]王越,晋建华,李思进,等.甲状腺24h摄碘率与131I治疗Graves甲亢疗效相关性研究[J].国际放射医学核医学杂志,2015,39(6):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
Wang Yue,Jin Jianhua,Li Sijin,et al.Correlation between thyroid 24 h of radioactive iodine uptake and clinical efficacy of 131I therapy for Graves’ hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
[14]郭坤,高蕊,于燕,等.表皮生长因子受体基因表达与甲状腺功能亢进症131I治疗预后的关系[J].国际放射医学核医学杂志,2015,39(1):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
Guo Kun,Gao Rui,Yu Yan,et al.The relationship between epidermal growth factor receptor mRNA expression and the efficacv of 131I treatment in hyperthyroidism patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
[15]孟召伟,谭建.解读美国甲状腺协会和临床内分泌医师协会2011年甲亢诊治指南[J].国际放射医学核医学杂志,2011,35(4):193.[doi:10.3760/cma.j.issn.1673-4114.2011.04.001]
MENG Zhao-wei,TAN Jian.Reading and analysis on management guidelines for hyperthyroidism published in 2011 by American Thyroid Association and American Association of Clinical Endocrinologists[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(1):193.[doi:10.3760/cma.j.issn.1673-4114.2011.04.001]
[16]孙琦婷,赵德善.Graves病甲状腺功能亢进症与血糖代谢[J].国际放射医学核医学杂志,2010,34(3):143.
SUN Qi-ting,ZHAO De-shan.Graves disease hyperthyroidism and glycometabolism[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(1):143.
[17]冯菲,赵德善.131I治疗青少年儿童甲状腺功能亢进症[J].国际放射医学核医学杂志,2009,33(3):171.[doi:10.3760/cma.j.issn.1673-4114.2009.03.011]
FENG Fei,ZHAO De-shan.The treatment of hyperthyroidism in adolescents and children with 131I[J].International Journal of Radiation Medicine and Nuclear Medicine,2009,33(1):171.[doi:10.3760/cma.j.issn.1673-4114.2009.03.011]
[18]汤建林,李玉莹,高柳艳,等.甲状腺功能亢进症治疗方法的比较和选择[J].国际放射医学核医学杂志,2009,33(3):175.[doi:10.3760/cma.j.issn.1673-4114.2009.03.012]
TANG Jian-lin,LI Yu-ying,GAO Liu-yan,et al.The methods and options of the treatment for hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2009,33(1):175.[doi:10.3760/cma.j.issn.1673-4114.2009.03.012]
[19]潘香颖,李慧贞.甲状腺功能亢进症伴肝功能受损的131I治疗疗效[J].国际放射医学核医学杂志,2009,33(3):179.[doi:10.3760/cma.j.issn.1673-4114.2009.03.013]
[20]王长修.甲状腺功能亢进症患者再次131I治疗的给药剂量对比研究[J].国际放射医学核医学杂志,2009,33(3):182.[doi:10.3760/cma.j.issn.1673-4114.2009.03.016]